Key facts
- This page summarizes Avraham Ben-Tzvi's Form 3 filing for Cyclacel Pharmaceuticals, Inc. (CYCC).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Jan 2025, 17:25.
Avraham Ben-Tzvi - 05 Jan 2025 Form 3 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)
- Reporting relationship
- Director
- Issuer ticker
- CYCC
- Reported as of
- 05 Jan 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 08 Jan 2025, 17:25:15 UTC
- Prior SEC filing
- 23 Oct 2024
- Next SEC filing
- 28 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Avraham Ben-Tzvi
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Avraham Ben-Tzvi filed Form 3 for Cyclacel Pharmaceuticals, Inc. (CYCC) on 08 Jan 2025.
Change
- Previous filing in this sequence was filed on 23 Oct 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CYCC
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 05 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
No securities are beneficially owned.